CWPH Building, Suite GD32
3280 Hospital Dr. NW
Calgary, AB T2N 4Z6
Phone: 403.220.2130
Fax: 403.270.3451
Email: Thomas.raedler@albertahealthservices.ca

Curriculum Vitae

Dr. med. habil. Thomas Joseph Raedler, MD

Born June 15th, 1963 in Munich, Germany

1. Professional Experience:
April 2007 until now:
2022 – ongoing: Associate Dean CME & PD, Cumming School of Medicine, University of Calgary
2020 – ongoing: Site-chief, Department of Psychiatry, Foothills Medical Centre
2016 – ongoing: CPD-Coordinator, Department of Psychiatry, University of Calgary, Cumming School of Medicine
2012 – ongoing: Medical Director, Mental Health Clinical Trials Unit (previously known as Psychopharmacology Research Unit – PRU), University of Calgary
2012 – ongoing: Member, Mathison Centre for Mental Health Research & Education
2012 – 2018: Psychiatry Clerkship Director, University of Calgary, Cumming School of Medicine
2012 – 2016: Member, HBI Education Committee
2009 – 2012: Psychiatry Evaluations Coordinator, University of Calgary, Cumming School of Medicine
2008 – 2015: Director of Resident Research, Department of Psychiatry, University of Calgary
2008 – 2009: Acting Medical Director, Early Psychosis Treatment Service
2007 – ongoing: Associate Professor, University of Calgary, Cumming School of Medicine, Department of Psychiatry, Calgary, AB, Canada
2007 – ongoing: Attending psychiatrist, Foothills Medical Centre
2007 – ongoing: Member, Hotchkiss Brain Institute (HBI), University of Calgary

August 1999 until April 2007:
Resident / attending psychiatrist at the Department of Psychiatry of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany (Director Dieter Naber)

I completed my habilitation through the University of Hamburg in July 2008

July 1996 until July 1999:
Fellowship as Visiting Associate at the Clinical Brain Disorders Branch (Chief Daniel Weinberger) at the National Institute of Mental Health in Bethesda, MD, USA
Main focus of research: SPECT-imaging as well as EEG/EP

October 1992 until June 1996:
Residency in Psychiatry at the Department of Psychiatry at St. Elizabeth's Medical Center of Boston, MA, USA

October 1991 until October 1992:
Doctoral Scholarship of the Technical University of Munich
Topic: "Evaluation of the role of HMPAO-SPECT, CT-scan and psychometric examination in establishing the diagnosis of Alzheimer's Disease"

June 1990 until December 1991:
Internship (Arzt im Praktikum) at the Alois-Alzheimer Clinic for Memory Disorders, Department of Psychiatry, Klinikum Rechts der Isar, Technical University of Munich (Director Hans Lauter)

May 1984 until June 1990:
Medical Studies at Ludwig-Maximilians-University in Munich, Germany
Graduated on 27th April 1990 with Great Distinction

Boards:
01/2005: Boards in Psychiatry (Board of Medicine, Hamburg, Germany)

Medical License:
2007 - ongoing: Specialist Medical License (Psychiatry), College of Physicians & Surgeons of Alberta, AB, Canada
1999 - 2009: Full Medical License, State of Hamburg, Germany
1994 - 2003: Full Medical License, Commonwealth of Massachusetts, USA
1992: Full Medical License, State of Bavaria, Germany
1992 - 1994: Limited Medical License, Commonwealth of Massachusetts, USA
1990 - 1992: Limited Medical License, State of Bavaria, Germany

Professional memberships:
AMA, APA, ASCP, CCNP, CINP, CMA, CPA, ECNP, IEPA, ISCTM, SIRS, SOBP

2. Bibliography (last 5 years):

Wagner E, Siskind D, Falkai P, Howes O, Correll C, Lee J, Honer WG, Kane JM, Fernandez-Egea E, Barnes TRE, Hasan A; TRRIP Working Group. Clozapine Optimization: A Delphi Consensus Guideline From the Treatment Response and Resistance in Psychosis Working Group. Schizophr Bull. 2023;49:962-972.
Andrea S, Papirny M, *Raedler T*. Brain Imaging in Adolescents and Young Adults With First-Episode Psychosis: A Retrospective Cohort Study. J Clin Psychiatry. 2019;80:18m12665.

3. Research Projects (last five years):

Project title: An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials. (CONNEX-X)
Funding: Boehringer Ingelheim
Period of support: 2023 - ongoing
Role in project: Principal Investigator

Project title: A Phase II, 6-week, multicenter, randomized, double-blind, double-dummy, placebo controlled, parallel group trial with a quetiapine arm to evaluate the efficacy, tolerability and safety of oral BI 1358894 in patients with Major Depressive Disorder with inadequate response to antidepressants.
Funding: Boehringer Ingelheim
Period of support: 2023 - ongoing
Role in project: Co-Investigator

Project title: A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia (CONNEX-1)
Funding: Boehringer Ingelheim
Period of support: 2022 - ongoing
Role in project: Principal Investigator

Project title: Feasibility and utility of administration of the Suicide Ideation and Behavior Assessment Tool (SIBAT) in the emergency department
Funding: Self funded
Period of support: 2022 - 2023
Role in project: Co-Investigator

Project Title: Survey of patients' interest for cannabis e-interventions (SPICE-T) to treat cannabis use disorder: Assessing preferences in young adults with psychosis
Funding: Health Canada and Ministère de la Santé et des Services sociaux du Québec
Period of support: 2022
Role in project: Co-Investigator

Project Title: Survey of patient interests for cannabis e-interventions (SPICE-P) to prevent cannabis-related harms: A preference survey for patients with early psychosis
Funding: Health Canada and Ministère de la Santé et des Services sociaux du Québec
Period of support: 2022
Role in project: Co-Investigator

Project Title: A Phase 4, Multicenter, Open-label, Interventional Trial to Assess the Effects on Engagement of Flexible-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy for the Treatment of Adults With Major Depressive Disorder
Funding: Otsuka Canada
Period of support: 2022
Role in project: Co-Investigator

Project title: A Phase 4, Canadian non-Interventional Trial to Assess Aripiprazole Once-Monthly for Schizophrenia, Schizoaffective Disorder and Bipolar I.
Funding: Otsuka Canada
Period of support: 2022 - 2023
Role in project: Co-Investigator

Project title: Evaluation of the Suicide Ideation and Behavior Assessment Tool (SIBAT) to detect changes over time in suicide risk factors over the course of an inpatient psychiatric admission
Funding: Self Funded
Period of support: 2021 - 2022
Role in project: Co-Investigator

Project Title: A Multicenter, 48-week Open-Label Safety Study of Adjunctive Troriluzole in Subjects with Obsessive Compulsive Disorder
Funding: Biohaven Pharmaceuticals, Inc
Period of support: 2021 - ongoing
Role in project: Co-Investigator

Project Title: A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Funding: Biohaven Pharmaceuticals, Inc
Period of support: 2021 - ongoing
Role in project: Co-Investigator

Project Title: A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 week treatment period in patients with schizophrenia (NCT03859973)
Funding: Boehringer-Ingelheim
Period of support: 2020 - 2023
Role in project: Principal Investigator

Project Title: Sexual Function and Relationship Status in Recent Onset Psychosis
Funding: Self-funded
Period of support: 2020 - 2022
Role in project: Principal Investigator

Project Title: A Phase IV, Real World, Open-label, Multi-centre Study on the Use of FOQUEST® (methylphenidate hydrochloride controlled-release capsules) for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Pediatric and Adult Patients (NCT04152629)
Funding: Purdue
Period of support: 2020 - 2021
Role in project: Co-Investigator

Project Title: A Study to Evaluate the Safety, Tolerability, and Effect of Risperidone Extended-Release Injectable Suspension (TV-46000) for Subcutaneous Use as Maintenance Treatment in Adult and Adolescent Patients with Schizophrenia (NCT03893825)
Funding: TEVA
Period of support: 2020
Role in project: Principal Investigator

Project Title: A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 52-week Treatment Period as an Early Intervention in Patients With Attenuated Psychosis Syndrome (NCT03230097)
Funding: Boehringer-Ingelheim
Period of support: 2018 - 2021
Role in Project: Principal Investigator

Project Title: A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 28-week Treatment Period as Adjunctive Therapy to Antipsychotic Treatment for the Prevention of Relapse in Patients With Schizophrenia (NCT03351244)
Funding: Boehringer-Ingelheim
Period of support: 2018 - 2021
Role in Project: Principal Investigator

Project Title: Study to Evaluate Safety & Efficacy of NaBen® as Add-on Treatment for Schizophrenia in Adults (NCT02261519)
Funding: SyneuRx International (Taiwan) Corp
Period of support: 2018 - 2023
Role in Project: Principal Investigator

Project Title: An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults (NCT03094429)
Funding: SyneuRx International (Taiwan) Corp
Period of support: 2018 - ongoing
Role in Project: Principal Investigator

Project Title: Lipid analysis and assessment of cognitive function in schizophrenia
Funding: Self-funded
Period of support: 2018 - 2022
Role in Project: Principal Investigator

Project Title: Adaptive Phase II Study to Evaluate the Safety & Efficacy of Sodium Benzoate as an Add-on Treatment for Schizophrenia in Adolescents (NCT01908192)
Funding Source: SyneuRx International (Taiwan) Corp
Period of Support: 2016 – 2023
Role in the Project: Principal Investigator

Project Title: Predictors and Mechanisms of Conversion to Psychosis - (NAPLS 3)
Funding Source: National Institute of Mental Health (NIMH)
Period of Support: 2014 - 2022
Role in the Project: Co-Investigator